These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 22580436)

  • 1. Interferon for ocular surface squamous neoplasia in 81 cases: outcomes based on the American Joint Committee on Cancer classification.
    Shields CL; Kaliki S; Kim HJ; Al-Dahmash S; Shah SU; Lally SE; Shields JA
    Cornea; 2013 Mar; 32(3):248-56. PubMed ID: 22580436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction.
    Kim HJ; Shields CL; Shah SU; Kaliki S; Lally SE
    Ophthalmology; 2012 May; 119(5):938-44. PubMed ID: 22361315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
    Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
    Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
    Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
    Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
    Blasi MA; Maceroni M; Sammarco MG; Pagliara MM
    Eur J Ophthalmol; 2018 Mar; 28(2):204-209. PubMed ID: 28967069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
    Boehm MD; Huang AJ
    Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
    Kusumesh R; Ambastha A; Sinha B; Kumar R
    Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical versus Medical Treatment of Ocular Surface Squamous Neoplasia: A Cost Comparison.
    Moon CS; Nanji AA; Galor A; McCollister KE; Karp CL
    Ophthalmology; 2016 Mar; 123(3):497-504. PubMed ID: 26686965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review.
    Karp CL; Galor A; Chhabra S; Barnes SD; Alfonso EC
    Ophthalmology; 2010 Dec; 117(12):2241-6. PubMed ID: 20619462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study.
    Galor A; Karp CL; Chhabra S; Barnes S; Alfonso EC
    Br J Ophthalmol; 2010 May; 94(5):551-4. PubMed ID: 19493859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
    Sturges A; Butt AL; Lai JE; Chodosh J
    Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Comparative Study of Topical Interferon α2b Versus Mitomycin C for Primary Ocular Surface Squamous Neoplasia.
    Kusumesh R; Ambastha A; Kumar S; Sinha BP; Imam N
    Cornea; 2017 Mar; 36(3):327-331. PubMed ID: 28079688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
    Schechter BA; Schrier A; Nagler RS; Smith EF; Velasquez GE
    Cornea; 2002 Jan; 21(1):6-11. PubMed ID: 11805499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression as a Possible Risk Factor for Interferon Nonresponse in Ocular Surface Squamous Neoplasia.
    Ashkenazy N; Karp CL; Wang G; Acosta CM; Galor A
    Cornea; 2017 Apr; 36(4):506-510. PubMed ID: 28129301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
    Alvarado-Castillo B; Santa Cruz-Pavlovich FJ; Gonzalez-Castillo C; Vidal-Paredes IA; Garcia-Benavides L; Rosales-Gradilla ME; Navarro-Partida J
    BMC Ophthalmol; 2023 Jul; 23(1):335. PubMed ID: 37501105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up.
    Krilis M; Tsang H; Coroneo M
    Ophthalmology; 2012 Oct; 119(10):1969-73. PubMed ID: 22704834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
    Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
    Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.
    Schechter BA; Koreishi AF; Karp CL; Feuer W
    Ophthalmology; 2008 Aug; 115(8):1291-6, 1296.e1. PubMed ID: 18187195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery Versus Interferon Alpha-2b Treatment Strategies for Ocular Surface Squamous Neoplasia: A Literature-Based Decision Analysis.
    Siedlecki AN; Tapp S; Tosteson AN; Larson RJ; Karp CL; Lietman T; Zegans ME
    Cornea; 2016 May; 35(5):613-8. PubMed ID: 26890663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular surface squamous neoplasia: analysis based on the 8th American Joint Committee on Cancer classification.
    Singh S; Mohamed A; Kaliki S
    Int Ophthalmol; 2019 Jun; 39(6):1283-1291. PubMed ID: 29749567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.